Background and objective Recent research has highlighted the fundamental role of
sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …

Objectives Sarcopenia is a syndrome characterized by reduced muscle mass and function. It
is well-recognized as a complication in chronic diseases such as chronic obstructive …

Background Sarcopenia gained importance in the evaluation of patients with chronic
respiratory diseases, including idiopathic pulmonary fibrosis (IPF), since it may impact …

Background Idiopathic pulmonary fibrosis (IPF) is relentless progressive interstitial lung
disease. Evaluating predictor of mortality for IPF patients is crucial. The aim of this study was …

Background Idiopathic pulmonary fibrosis (IPF) is a rare and serious disease characterized
by progressive lung-function loss. Limited evidence has been published on the impact of …

Aim of the study: Potential care implications of antifibrotic reimbursement restrictions were
studied by forced vital capacity (FVC) decline, mortality and specialty care related healthcare …

Research question There is no widely accepted grading system for IPF disease severity,
although physiologic impairment based on pulmonary function testing is frequently …

Purpose Real-world studies have reported reduced mortality in patients with idiopathic
pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or …

Rationale Longitudinal data on the impact of continued, switched or discontinued antifibrotic
therapy in patients with idiopathic pulmonary fibrosis (IPF) who have disease progression is …